Inovio Pharmaceuticals Inc vs Live Nation Entertainment, Inc. — how do they compare? Inovio Pharmaceuticals Inc trades at $0.76 (market cap $78.55M), while Live Nation Entertainment, Inc. trades at $184.51 (market cap $42.71B). The key difference: Live Nation Entertainment, Inc. is far larger — about 543.7× Inovio Pharmaceuticals Inc's market cap, and Live Nation Entertainment, Inc. is trading nearer its 52-week high, Inovio Pharmaceuticals Inc nearer its low. Which is the better fit depends on your goals.
| INO | LYV | |
|---|---|---|
Market Cap | $78.55M | $42.71B |
Sector | Health | Industrials |
52-Week High | $2.87 | $186.59 |
52-Week Low | $0.66 | $125.61 |
Enterprise Value | $49.56M | $44.92B |
Signals from Pluang's Aura AI — not financial advice
INO shares trade at $0.74, up 10.24% today, but remain significantly below analyst consensus targets. The biotech firm shows improving operational trends with three consecutive quarterly earnings beats, though financials reveal substantial losses with -130% net margin. Technical indicators signal bearish momentum despite neutral oscillators. Key catalyst is the FDA's October 30, 2026 PDUFA date for INO-3107, with the company recently raising $20 million to fund operations.
Outlook hinges on FDA approval of INO-3107, representing a binary event that could drive substantial upside given the $3.25 consensus target. However, persistent cash burn, negative profitability metrics, and ongoing shareholder litigation pose significant risks. The stock offers high-risk, event-driven potential for speculative investors willing to accept regulatory and financial uncertainty.
LYV trades at $184.64, up 2.2% on the day, with a bullish technical signal from moving averages and strong analyst support (86.96% buy ratings). The company reported Q2 2026 EPS of $1.05, beating estimates, and revenue growth driven by record concert demand. However, valuation metrics like a P/E of 117.49 and negative ROE of -116.65% highlight significant premium pricing and profitability challenges.
Outlook remains positive due to robust live event demand and raised full-year expectations, but risks include high debt, legal uncertainties, and margin pressure. The consensus price target of $209.54 suggests ~13.5% upside, though investors should weigh growth potential against elevated valuation and operational risks.
Trailing returns across standard periods
Inovio Pharmaceuticals Inc is a United States based biotechnology company that develops active DNA-based immunotherapies and vaccines to treat and prevent cancers and infectious diseases. The company is engaged in gene therapy, where its immunotherapy platform consists of DNA-based immunotherapy and electroporation delivery technologies.
Read more on INO →Live Nation is the largest live entertainment firm in the world with over 570 million fans served in 44 countries in 2018 by the company's concert and ticketing platforms. Via either owning, operating, or holding exclusive booking rights, Live Nation controls over 235 venues including the House of Blues, the Hollywood Palladium, and Spark Arena in New Zealand. Live Nation also owns one of the largest ticketing services, Ticketmaster, which sold over 480 million tickets for over 12,000 clients in 2018. The firm's artist management agencies have over 400 clients. This large live entertainment footprint helped Live Nation become one of the largest advertising and sponsorship platforms aimed at music fans. Liberty Media owns 33% of Live Nation, held under its SiriusXM tracking stock.
Read more on LYV →